Health
Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test – News-Medical.net
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce…
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.
Avacta is developing several coronavirus tests using Affimer binders that are highly…
-
General22 hours agoThe ABC and Ms Lattouf
-
General21 hours agoHuman remains located, police make arrest in search for Sunbury man Joshua Bishop
-
General22 hours ago‘Heartbreaking’ algal bloom hits metropolitan Adelaide beaches
-
General11 hours agoG7 agrees to avoid higher taxes for US, UK companies